Back to News
Market Impact: 0.1
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Source: GlobeNewswire
Healthcare & BiotechPrivate Markets & Venture
The article fragment says Dr. Eckler has more than two decades of healthcare investing experience across public and private markets, including roles at Samsara BioCapital, ArrowMark, and GMT Capital, as well as scientific research experience. It provides no further event, figures, or market implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Nvidia-backed Reflection AI unveils its first open model, Beam. Could it be America’s best chance to compete with China?
- Up 57% since June: this AI-picked pharma stock keeps climbing
- Why is NeoGenomics stock sliding today?
- Nvidia backs startup Reactor as buzz grows for world models
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data